MannKind Slides on News
- On 10:05 am EDT, Wednesday October 7, 2009
Yesterday, shares of MannKind Corporation (NasdaqGM: MNKD - News) lost more than 30% following the disappointing news about the company’s proposed partnership deal for Afresa, its inhaled insulin product. MannKind stated, in a filing with the SEC, that the company will not be able to enter into a deal by year end, as was earlier expected.
Although the company announced that it has made some progress in the partnership deal, we believe that any potential partner would wait for US Food and Drug Administration (FDA) approval to come before entering into any agreement.
MannKind is seeking FDA approval of Afresa for the treatment of type I and type II diabetes. With a Prescription Drug User Fee Act (PDUFA) date of January 16, 2010 for Afresa, we believe a partnership deal is not likely before that.
The approval of Afresa is significant not only from the company’s perspective but the medical community as a whole. While there were many late-stage drugs under development in the inhaled insulin field a few years back, competition is virtually absent now.
The change in the competitive landscape began with Pfizer’s (NYSE: PFE - News) withdrawal of Exubera from the market in October 2007. Additionally, Pfizer stated that a few diabetic patients on Exubera developed lung cancer. Following the disappointing performance of Exubera, other big players including Novo Nordisk (NYSE: NVO - News) and Eli Lilly (NYSE: LLY - News) discontinued their inhaled insulin programs, citing the lack of confidence in the regulatory environment and market prospects for an inhaled insulin product.
While the number of lung cancer cases was too few to conclusively link Exubera to the disease, the results still cast a looming shadow on the future of Afresa. Moreover, we believe regulatory hurdle will become a steep climb for MannKind with the FDA likely to ask for more stringent and extensive study data. We have a Neutral recommendation on the stock.
MANNKIND CP (MNKD): Read the Full Research Report
PFIZER INC (PFE): Read the Full Research Report
ELI LILLY & CO (LLY): Read the Full Research Report
|
Related Headlines
- 12 Years Of Patent Protection For Biologics Based Research And Development Creates Buying Opportunity In Biotech Stocks - Wall Street Transcript
- Increase In Patent Protection For Biologics Creates Significant Upside For Drug Development Enterprise Valuations - Wall Street Transcript
- TradingMarkets 7 Stocks You Need to Know for Monday - TradingMarkets.com
- Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows - PR Newswire
- INSIDE WASHINGTON: Stream of WH health care visits - AP
Related Blog Headlines
- Byetta Label Revised - Zacks.com
- 5 Good Dividend Plays - at Seeking Alpha
- Pfizer Increases R&D Commitment in China - at Seeking Alpha
- Novartis Deal Gives Incyte a Boost - at Seeking Alpha
- Pfizer, Spanning the Globe to Defend Lipitor Patents - at The Wall Street Journal Online
Sponsored Links
-
Trade Stocks? Try Currency Trading
Trade in a highly trending market 24-hrs a day, 5.5 days a week. GFT. -
Earn From 1.90% to 2.20% Apply Online
With GE Capital Corporation. Not An Offer Of Securities For Sale.
-
Buy Stocks for $4
No account or investment minimums. No inactivity fees. Start Today. -
Super Cheap Car Insurance Quotes
Get Discount Auto Insurance Quotes Online - Rates from $15 / Month.
More From Provider
Tech Ticker Recent Posts
Add Alert © 2009 Zacks.com. All rights reserved.